Retrophin Sinks as Drug ?Pharma Bro? Martin Shkreli Co-Invented Fails

Retrophin, the drug developer founded by jailed former biotech executive Martin Shkreli, has failed its first big test. The San Diego-based company?s experimental drug fosmetpantotenate failed a Phase 3 trial, FORT, in patients with a rare and deadly neurological disorder called pantothenate kinase-associated neurodegeneration, or PKAN. The Retrophin (NASDAQ: RTRX) drug flunked all of its [?]